Boehringer, Lilly's Tradjenta meets in first CV outcomes trial

Boehringer Ingelheim GmbH (Ingelheim, Germany) and partner Eli Lilly and Co. (NYSE:LLY) said Tradjenta linagliptin met the primary endpoint of improving time to first occurrence of a major

Read the full 284 word article

User Sign In